LEE'S PHARM (00950) announced its interim results, reporting a profit attributable to shareholders of HKD 95.014 million, a year-on-year increase of 41.4%.

LEE'S PHARM (00950) announced its interim results for 2026, with revenues of approximately HKD 797 million, a year-on-year increase of 14.6%. Profit attributable to equity holders amounted to HKD 95.014 million, reflecting a year-on-year growth of 41.4%. Earnings per share were HKD 0.1614, and the interim dividend was HKD 0.035 per share. Among these, revenues from introduced products increased by 24.3% to approximately HKD 337 million, mainly driven by contributions from Fepra , Budesonide , Quetiapine , and Resubulin . Revenues from patent and generic products rose by 8.4% to HKD 459 million, primarily attributable to contributions from Socazolizumab injection, Shanke Yut (after the addition of an indication for extensive-stage small cell lung cancer), Youjingan, Treprostinil injection Rui Nier, Azilsartan tablets Qidampin, and Sulodexide injection Lichangqing, which offset the decline in Naquheparin calcium injection Litenqing due to price reductions from centralized procurement.